5-HT2A receptor binding is reduced in drug-naive and unchanged in SSRI-responder depressed patients compared to healthy controls: a PET study

ObjectiveThe aim of the study was to investigate differences in 5-HT2A receptor binding between healthy volunteers and patients with major depressive disorder (MDD), either never treated before with antidepressants (drug-naive: DN) or responding to paroxetine treatment (drug-treated: DT).MethodsNineteen DN patients with MDD and 15 euthymic DT (paroxetine 4 weeks) patients were compared with a group of 20 healthy controls (C) with positron emission tomography (PET) using [18F]fluoroethylspiperone ([18F]FESP), a 5-HT2A and D2 receptor antagonist. A "binding index" (BI) of [18F]FESP to cortical and basal ganglia regions was calculated as the ratio of the activity in these regions to that of cerebellum. Differences in BI between groups, i.e. C versus DN or DT, were assessed by ANOVA, with or without age as covariate (ANCOVA).ResultsA significant reduction in BI (P=0.003 ANOVA, P=0.001 ANCOVA) was found in DN patients in the frontal, occipital, temporal and cingulate cortices, but not in the striatum. No significant differences emerged between C and DT patients.ConclusionsThe reduction of [18F]FESP BI in cortical areas of DN depressed, but not of euthymic DT patients suggests an association between the occurrence of depressive symptoms and impairment of cortical 5-HT2A receptors. [18F]FESP cortical BI may represent a state marker of depression.

[1]  C. Katona,et al.  Brain 5-HT2 receptor binding sites in depressed suicide victims , 1988, Brain Research.

[2]  Wolfgang Gaebel,et al.  Dopamine D2 receptor binding before and after treatment of major depression measured by [123I]IBZM SPECT , 1999, Psychiatry Research: Neuroimaging.

[3]  J. Palacios,et al.  Serotonin receptors in the human brain. II. Characterization and autoradiographic localization of 5-HT1C and 5-HT2 recognition sites , 1986, Brain Research.

[4]  H. Meltzer,et al.  Increased serotonin2 (5-HT2) receptor binding as measured by 3H-lysergic acid diethylamide (3H-LSD) in the blood platelets of depressed patients. , 1989, Life sciences.

[5]  B. McEwen,et al.  Increased serotonin2 and beta-adrenergic receptor binding in the frontal cortices of suicide victims. , 1986, Archives of general psychiatry.

[6]  E. Smeraldi,et al.  Increased 5-Hydroxytryptamine-2 Receptor Binding in the Frontal Cortex of Depressed Patients Responding to Paroxetine Treatment: A Positron Emission Tomography Scan Study , 2001, Journal of clinical psychopharmacology.

[7]  P. Liddle,et al.  Decrease in brain serotonin 2 receptor binding in patients with major depression following desipramine treatment: a positron emission tomography study with fluorine-18-labeled setoperone. , 1999, Archives of general psychiatry.

[8]  V. Arango,et al.  Autoradiographic demonstration of increased serotonin 5-HT2 and beta-adrenergic receptor binding sites in the brain of suicide victims. , 1990, Archives of general psychiatry.

[9]  G. Sedvall,et al.  Autoradiographic localization of 5‐HT2A receptors in the human brain using [3H]M100907 and [11C]M100907 , 2000, Synapse.

[10]  S. Kapur,et al.  Prefrontal cortex 5-HT2 receptors in depression: an [18F]setoperone PET imaging study. , 1999, The American journal of psychiatry.

[11]  Y. Sheline.  3D MRI studies of neuroanatomic changes in unipolar major depression: the role of stress and medical comorbidity , 2000, Biological Psychiatry.

[12]  Patrick Dupont,et al.  Visualisation of loss of 5-HT2A receptors with age in healthy volunteers using [18F]altanserin and positron emission tomographic imaging , 1996, Psychiatry Research: Neuroimaging.

[13]  F. Belpaire,et al.  In-vitro characterization of the cytochrome P450 isoenzymes involved in the back oxidation and N-dealkylation of reduced haloperidol. , 1998, Pharmacogenetics.

[14]  E. Corruble,et al.  Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors , 1997, Psychopharmacology.

[15]  B. Mulsant,et al.  PET imaging of serotonin type 2A receptors in late-life neuropsychiatric disorders. , 1999, The American journal of psychiatry.

[16]  L. Friedman,et al.  Meta-analyses of studies of ventricular enlargement and cortical sulcal prominence in mood disorders. Comparisons with controls or patients with schizophrenia. , 1995, Archives of general psychiatry.

[17]  J. Marcusson,et al.  Brain 5-HT1A, 5-HT1D, and 5-HT2 Receptors in suicide victims , 1994, Biological Psychiatry.

[18]  G. Rajkowska,et al.  Postmortem studies in mood disorders indicate altered numbers of neurons and glial cells , 2000, Biological Psychiatry.

[19]  J. Mann,et al.  INCREASED SEROTONIN-2 BINDING SITES IN FRONTAL CORTEX OF SUICIDE VICTIMS , 1983, The Lancet.

[20]  P. Cowen,et al.  Platelet 5-HT receptor binding during depressive illness and tricyclic antidepressant treatment. , 1987, Journal of affective disorders.

[21]  Stephen M Strakowski,et al.  Volumetric MRI studies of mood disorders: do they distinguish unipolar and bipolar disorder? , 2002, Bipolar disorders.

[22]  C Crouzel,et al.  Loss of brain 5-HT2 receptors in Alzheimer's disease. In vivo assessment with positron emission tomography and [18F]setoperone. , 1993, Brain : a journal of neurology.

[23]  A. Bossuyt,et al.  Dopamine D2 receptors in depression measured with single photon emission computed tomography , 1994, Biological Psychiatry.

[24]  H. Feistel,et al.  Dopamine and depression — Striatal dopamine D2 receptor SPECT before and after antidepressant therapy , 1996, Psychopharmacology.

[25]  J. Mazziotta,et al.  No-carrier-added 3-(2'-[18F]fluoroethyl)spiperone, a new dopamine receptor-binding tracer for positron emission tomography. , 1986, International journal of radiation applications and instrumentation. Part B, Nuclear medicine and biology.

[26]  B. Mazoyer,et al.  The cortical serotonin2 receptors studied with positron-emission tomography and [18F]-setoperone during depressive illness and antidepressant treatment with clomipramine , 1999, Biological Psychiatry.

[27]  C. Katona,et al.  Brain 5-HT2 receptors in suicide victims: violence of death, depression and effects of antidepressant treatment , 1994, Brain Research.

[28]  Klaus P. Ebmeier,et al.  Clinical and psychometric correlates of dopamine D2 binding in depression , 1997, Psychological Medicine.

[29]  F. Fazio,et al.  Effects of Fluvoxamine Treatment on the in Vivo Binding of [F-18]FESP in Drug Naive Depressed Patients: A Pet Study , 2000, NeuroImage.

[30]  H. Müller-Gärtner,et al.  In VivoEvidence for the Involvement of Dopamine-D2Receptors in Striatum and Anterior Cingulate Gyrus in Major Depression , 1997, NeuroImage.

[31]  Trevor Sharp,et al.  A review of central 5-HT receptors and their function , 1999, Neuropharmacology.

[32]  P. Liddle,et al.  Brain serotonin2 receptors in major depression: a positron emission tomography study. , 2000, Archives of general psychiatry.

[33]  M. Folstein,et al.  EFFECTS OF AGE ON DOPAMINE AND SEROTONIN RECEPTORS MEASURED BY POSITRON TOMOGRAPHY IN THE LIVING HUMAN BRAIN , 1984, Science.

[34]  Anat Biegon,et al.  Autoradiographic analysis of [3H]ketanserin binding in the human brain postmortem: effect of suicide , 1990, Brain Research.

[35]  S. Fahn,et al.  Clonazepam-induced up-regulation of serotonin1 and serotonin2 binding sites in rat frontal cortex. , 1986, Advances in neurology.

[36]  J. Mendlewicz,et al.  Serotonin 5-HT2 receptor imaging in major depression: focal changes in orbito-insular cortex , 1997, British Journal of Psychiatry.

[37]  Robert B Innis,et al.  Imaging of the serotonergic system: interactions of neuroanatomical and functional abnormalities of depression , 1998, Biological Psychiatry.